Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Altimmune Inc.
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Despite double-digit weight loss across several drugs presented at ADA, experts note access to obesity therapies will be constrained without outcomes data to justify their widespread use and cost.
Deal brings Lilly a Phase II activin receptor-targeting antibody that could provide another tool in battling obesity. This is Lilly’s fourth M&A transaction since 20 June.
While progress in NASH has been slow for years, two dual GLP-1/GR agonists from rivals Merck & Co and Altimmune are showing mid-stage promise.
- Other Names / Subsidiaries
- Immune Targeting Systems (ITS) Ltd.
- ImmuneFocus Corporation
- PharmAthene Inc.
- Spitfire Pharma, Inc.
- Vaxin Pharmaceuticals
- Vaxin Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.